# US 2021/0046045 A1 · Methods and compositions associated with the granulocyte colony-stimulating factor receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0046045 A1
- Document ID: US20210046045A1
- Status: Published application
- Kind: A1
- Application number: 16/925,926
- Filed: 2020-07-10
- Published: 2021-02-18
- Earliest claimed: 2011-11-14
- Assignees: Ligand Pharmaceuticals Incorporated
- Applicants: Ligand Pharmaceuticals, Inc.
- Inventors: Lin Zhi; Keith Marschke; Virginia H. Grant; Steven L. Roach; Yixing Shen; Jason C. Pickens; Bijan Pedram; Cornelis Arjan van Oeveren; Lino J. Valdez; Andrew R. Hudson
- Web page: https://patentgrep.com/patent/US20210046045A1

## CPC

- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/4152: having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 209/34: in position 2
- C07D 231/46: Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C07D 231/52: Oxygen atom in position 3 and nitrogen atom in position 5, or vice versa
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C12Q 1/18: Testing for antimicrobial activity of a material
- C12Q 1/66: involving luciferase
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A compound of Formula (II), wherein the compound of Formula (II) has the following structure:
a tautomer thereof, or a pharmaceutically acceptable salt thereof,
wherein:
R2 or R3 is selected from hydrogen, an optionally substituted C1-C6 alkyl, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C1-C6 heteroalkyl, an optionally substituted C3-C8 cycloalkyl, an optionally substituted C3-C8 cycloalkenyl, an optionally substituted C1-C6 heterocycle, an optionally substituted aryl, and an optionally substituted heteroaryl;
R4 is selected from hydrogen, an optionally substituted C1-C6 alkyl, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C1-C6 heteroalkyl, an optionally substituted C3-C8 cycloalkyl, an optionally substituted C3-C8 cycloalkenyl, an optionally substituted C1-C6 heterocycle, an optionally substituted heteroaryl, and an optionally substituted heteroarylalkyl;
R9 is selected from hydrogen, an optionally substituted C1-C6 alkyl, an optionally substituted C2-C6 alkenyl, an optionally substituted C2-C6 alkynyl, an optionally substituted C1-C6 heteroalkyl, an optionally substituted C3-C8 cycloalkyl, an optionally substituted C3-C8 cycloalkenyl, an optionally substituted C1-C6 heterocycle, an optionally substituted heteroaryl, an optionally substituted arylalkyl, an optionally substituted arylalkenyl, an optionally substituted arylalkynyl, an optionally substituted heteroarylalkyl, an optionally substituted heteroarylalkenyl, and an optionally substituted heteroarylalkynyl;
W is selected from O (oxygen) and NH;
X is N (nitrogen) or CR2; and
Y is selected from an optionally substituted C1-C6 alkyl, C2-C6 alkenyl, an optionally substituted C1-C6 heteroalkyl, an optionally substituted C1-C6 heteroalkenyl, an optionally substituted phenylalkenyl, and an optionally substituted heterocyclealkenyl.

### Claim 22 (depends on 21)

The compound of claim 21, wherein W is NH.

### Claim 23 (depends on 21)

The compound of claim 21, wherein X is N.

### Claim 24 (depends on 21)

The compound of claim 21, wherein the compound has the structure of Formula (IIa) or (IIb):
a tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein:
R3 is selected from hydrogen, an optionally substituted C1-C6 alkyl, an optionally substituted C3-C8 cycloalkyl, an optionally substituted C1-C6 heterocycle, an optionally substituted aryl, and an optionally substituted heteroaryl;
R4 is selected from an optionally substituted C1-C6 alkyl, an optionally substituted C3-C8 cycloalkyl, an optionally substituted C1-C6 heterocyclyl; and
R9 is selected from hydrogen, an optionally substituted C1-C6 alkyl, an optionally substituted C3-C8 cycloalkyl, an optionally substituted C1-C6 heterocyclyl, an optionally substituted heteroaryl, an optionally substituted arylalkyl, and an optionally substituted heteroarylalkyl.

### Claim 25 (depends on 24)

The compound of claim 24, wherein the compound has the structure of Formula (IIa):
a tautomer thereof, or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 24)

The compound of claim 24, wherein the compound has the structure of Formula (IIb):
a tautomer thereof, or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 24)

The compound of claim 24, wherein:
R3 is selected from hydrogen, and an optionally substituted C1-C3 alkyl;
R4 is selected from an optionally substituted C1-C6 alkyl, an optionally substituted C3-C8 cycloalkyl; and
R9 is selected from an optionally substituted C1-C6 alkyl, an optionally substituted arylalkyl, an optionally substituted arylalkenyl, an optionally substituted arylalkynyl, and an optionally substituted heteroarylalkyl.

### Claim 28 (depends on 27)

The compound of claim 27, wherein:
R3 is an optionally substituted C1-C3 alkyl;
R4 is an optionally substituted C1-C4 alkyl; and
R9 is selected from an optionally substituted C1-C3 alkyl, an optionally substituted arylalkyl, an optionally substituted arylalkenyl, and an optionally substituted arylalkynyl.

### Claim 29 (depends on 28)

The compound of claim 28, wherein R3 is a C1-C4 alkyl.

### Claim 30 (depends on 29)

The compound of claim 29, wherein R3 is methyl.

### Claim 31 (depends on 28)

The compound of claim 28, wherein R4 is a C1-C4 alkyl substituted with hydroxy, cyano, or phenyl.

### Claim 32 (depends on 31)

The compound of claim 31, wherein R4 is a C1-C4 alkyl substituted with hydroxy.

### Claim 33 (depends on 21)

The compound of claim 21, wherein the compound is selected from the group consisting of:
a tautomer thereof, or pharmaceutically acceptable salt thereof.

### Claim 34 (depends on 21)

The compound of claim 21, wherein the compound is:

### Claim 35 (depends on 21)

A pharmaceutical composition comprising the compound of claim 21 and a pharmaceutically acceptable excipient.
